Apellis Pharmaceuticals shares rally on Syfovre approval
Investing.com | Author Sam Boughedda
Published Feb 21, 2023 11:17AM ET
Updated Feb 21, 2023 11:30AM ET
Apellis Pharmaceuticals (APLS) shares rally on SYFOVRE approval
By Sam Boughedda
The U.S. Food and Drug Administration (FDA) has approved Apellis Pharmaceuticals' (NASDAQ:APLS) Syfovre for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), the company announced Tuesday.
The approval to treat GA is based on positive results from the Phase 3 OAKS and DERBY studies at 24 months. Syfovre is the first and only FDA-approved treatment for GA.
"Today marks an extraordinary milestone for patients, the retina community, and Apellis. With its increasing effects over time and flexible dosing, we believe that Syfovre will make a meaningful difference in the lives of people with GA," commented Cedric Francois, co-founder and chief executive officer of Apellis.
Apellis shares are currently up more than 10% on the news.
Reacting to the announcement, Stifel analysts told investors in a research note that the approval locks in the biopharmaceutical company's first-to-market position and quiets "lingering concerns after an unconventional regulatory process."
"Importantly, Syfovre gained a broad label with treatment indicated for intervals every 24-60 days—giving flexibility to dose according to patient needs—and no unexpected safety findings over 24 months," the analysts wrote. "Given the unusual developments during review, we expect APLS shares to finally break out of its volatile range."
BofA analysts maintained a Buy rating on the stock but lifted the price target to $115 from $79, stating that Apellis management's "mic drop moment arrives."
"Overall, we are very encouraged by today's update as the approval confirms our long-standing thesis that the totality of data and high unmet need warrant peg's approval in GA," said the analysts.
"Our recent doctor checks suggest that both doctors and patients are excited about Syfovre's adoption. Our doctors expect to use the drug in 20-50% of their pts and anticipate 70-80% compliance rate with EOM use preference. We model 2023 and 2024 sales estimates of $70mn and $240mn, respectively."
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.